MétaCan
Menu
← Back to cohort
Record W1973680761 · doi:10.1158/1538-7445.am10-3486

Abstract 3486: Interaction of flaxseed oil with trastuzumab in HER2 overexpressing human breast tumors (BT-474)

2010· article· en· W1973680761 on OpenAlexaff
Julie K. Mason, Jianmin Chen, Lilian U. Thompson

Bibliographic record

VenueCancer Research · 2010
Typearticle
Languageen
FieldNursing
TopicFatty Acid Research and Health
Canadian institutionsUniversity of Toronto
Fundersnot available
KeywordsMedicineTrastuzumabBreast cancerEstrogen receptorInternal medicineImmunohistochemistryCancerOncologyEndocrinology

Abstract

fetched live from OpenAlex

Abstract BACKGROUND: Trastuzumab (TRAS) is a first line therapy for breast tumors that overexpress the human epidermal growth factor receptor 2 (HER2) but tumors develop resistance within one year of treatment. Flaxseed oil (FO) rich in n-3 fatty acid alpha linolenic acid (ALA) has been shown to reduce HER2 expression and signalling in estrogen receptor positive human breast tumors. Our objective was to determine whether combining dietary FO with TRAS treatment will enhance TRAS effectiveness in reducing tumor growth. METHODS: Ovariectomized mice with established HER2 overxpressing tumors (BT-474) and estrogen pellet implant were fed the basal diet (BD) (control) or treated with TRAS (1 or 2.5mg/kg body weight) and fed either the BD or BD supplemented with 4% FO for 4 weeks. Palpable tumor area was measured weekly. After animal sacrifice, excised tumors were analyzed using immunohistochemistry for cell proliferation (Ki-67) and apoptosis and using Western blot analysis for HER2, MAPK and Akt. RESULTS: Tumors in the control, TRAS1, TRAS2.5, and TRAS1+FO, had palpable tumor areas that significantly increased (p<0.05) by 164%, 104%, 60% and 107%, respectively at the end of the study compared to week 0 while tumors in the FO+TRAS2.5 group did not significantly increase in size. FO+TRAS2.5 treated tumors also had significantly lower (p<0.05) palpable tumor area compared to the TRAS2.5 and other treated tumors at week 4. There was no difference in palpable tumor area between TRAS1 and FO+TRAS1 treated tumors. FO+TRAS2.5 caused a 39% greater increase in apoptosis (p<0.05) and a 61% greater reduction in cell proliferation (p<0.05) compared to TRAS2.5 treatment alone. Western blots support these results and indicate enhanced reductions in HER2, MAPK and Akt expression when TRAS2.5 treatment was combined with dietary FO. CONCLUSIONS: ALA-rich FO enhanced the effectiveness of TRAS at 2.5mg/kg in reducing tumor growth and the mechanisms may involve reduced cell proliferation and increased apoptosis through modulation of HER2 signalling pathways. This is significant as it could lead to a simple, inexpensive complementary treatment for HER2+ patients being treated with TRAS. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3486.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.007

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.062
GPT teacher head0.432
Teacher spread0.370 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2010
Admission routes1
Has abstractyes

Explore more

Same venueCancer Research→Same topicFatty Acid Research and Health→French-language works237,207→